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ABSTRACT
Substantial increases in antimicrobial resistance among Gram-positive pathogens, particularly Staphylo-
coccus aureus, are compromising traditional therapies for serious bacterial infections. There has been
an alarming increase in the rates of methicillin-resistant S. aureus (MRSA) over the past two decades,
and the more recent emergence of heterogenous vancomycin-intermediate (hVISA), vancomycin-
intermediate (VISA) and vancomycin-resistant S. aureus (VRSA) strains limits the use of vancomycin, the
current standard of care for MRSA infections. Tolerance to vancomycin, which represents a lack of
bactericidal activity of vancomycin, is another troublesome property of some S. aureus strains that can
adversely affect the outcome of antimicrobial therapy. Increasing MICs of vancomycin for staphylococci,
poor tissue penetration by the drug and a slow rate of bactericidal action of the drug have also raised
concerns about its efﬁcacy in the contemporary treatment of MRSA infections. There is an increasingly
apparent need for new agents for the treatment of staphylococcal infections, ideally with potent
bactericidal activity against MRSA, hVISA, VISA and VRSA and with superior susceptibility proﬁles as
compared with glycopeptides.
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INTRODUCTION
Over the past two decades, there has been a shift
in the epidemiology of serious bacterial infec-
tions, with an increasing proportion being attrib-
utable to Gram-positive bacteria [1–3], which
have become the predominant cause of many
infections [4,5]. This trend is especially apparent
for bloodstream infections, where Gram-positive
pathogens can account for up to 70% of infec-
tions, and for surgical site infections, where the
predominant cause has shifted from Gram-nega-
tive bacteria to Gram-positive bacteria over the
past 20 years [4]. Consistent with these ﬁndings,
coagulase-negative staphylococci, Staphylococcus
aureus and enterococci were the most frequently
isolated species from monomicrobial nosocomial
bloodstream infections in US hospitals from 1995
to 2002, with incidences of 31.3%, 20.2% and
9.4%, respectively [6]. The increasing association
of S. aureus with serious infections is of particular
concern. In data from the US National Nosoco-
mial Infections Surveillance System, the percent-
age of S. aureus isolates from urinary tract
infections and pneumonia cases approximately
doubled between 1975 and 2003 [4]. In addition,
the SENTRY Antimicrobial Surveillance Program
ranks S. aureus as the primary cause of skin and
soft tissue infections (SSTIs) in Europe, North
America and Latin America, with the highest
occurrence being in North America (51.6% in
2004) [7].
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THE SHIFTING EPIDEMIOLOGY OF
STAPHYLOCOCCAL
ANTIMICROBIAL RESISTANCE
There has been a substantial increase in resistance
to antimicrobial agents among bacterial patho-
gens, particularly in Gram-positive bacteria,
which is compromising traditional therapies [8].
The prevalence of methicillin-resistant S. aureus
(MRSA) is increasing signiﬁcantly in many parts
of the world [6,9], with resistance rates being
higher than 50% in the USA [6] and some
European countries [9]. Over the past decade,
MRSA rates doubled in SENTRY program med-
ical centres in the USA, from 27% in 1997 to 54%
in 2006. In US intensive care units speciﬁcally, a
doubling of MRSA rates was also observed over
the period 1989–2003, with the most recent
resistance rates being in excess of 60% (National
Nosocomial Infections Surveillance System;
http://www.cdc.gov/ncidod/dhqp/nnis.html; acc-
essed 31 January 2007). Methicillin resistance in
coagulase-negative staphylococci has also been
increasing, from just over 70% resistance in
isolates between 1995 and 1997 to over 80%
between 2000 and 2002 in the USA [6].
Vancomycin is currently the drug of choice for
the treatment of MRSA, but its use is being
compromised by the recent emergence of vanco-
mycin-intermediate or -resistant S. aureus (VISA
and VRSA) strains [10]. The clinical signiﬁcance of
MRSA infection in S. aureus bacteraemia is high-
lighted by the elevated rates of associated mor-
tality as compared with those seen in infection
with methicillin-susceptible S. aureus (MSSA).
Two separate meta-analyses have demonstrated
that infection with MRSA is associated with a
higher mortality rate than infection with MSSA
(29% vs 12%, p < 0.001 [11]; 36% vs 23%,
p < 0.001 [12]).
Increasing rates of MRSA infection have been
accompanied by the emergence of MRSA isolates
among healthy individuals in the community
without apparent traditional risk-factors [13].
Community-acquired MRSA (CA-MRSA) infec-
tions have been reported worldwide [14], and are
now regarded as a serious public health problem
[15]. CA-MRSA strains are distinct from hospital-
acquired strains and are characteristically more
virulent, but also more susceptible to non-b-
lactam antimicrobials, such as clindamycin, tri-
methoprim–sulfamethoxazole and tetracyclines
such as doxycycline [16]. CA-MRSA strains fre-
quently contain the staphylococcal chromosome
cassette (SCC) mec type IV, which contains mecA,
the resistance gene against b-lactam agents [16].
SCC mec type IV is smaller than the cassettes
usually found in hospital strains of MRSA, pri-
marily due to the absence of non-b-lactam resis-
tance genes, which may make it particularly
efﬁcient in transferring resistance among bacteria
[16]. CA-MRSA strains are also associated with
greater toxin production; most strains carry the
Panton–Valentine leukocidin genes [16], which
encode cytotoxins that can cause tissue necrosis
and leukocyte destruction [17]. Panton–Valentine
leukocidin is mainly associated with severe com-
munity-acquired primary skin infections and
necrotising pneumonia [17].
SSTIs are by far the most common clinical
manifestations in CA-MRSA cases, and have been
reported to represent 75–77% of such cases in US
patient cohorts [15,18]. Other types of infections
caused by CA-MRSA, occurring at much lower
frequencies, include: wound infections (10%) [15],
otitis media (7%) [18], respiratory tract infections
(2–6%) [15,18], bacteraemia (3–4%) [15,18], sinus
infections (4%) [15] and urinary tract infections
(1–4%) [15,18]. Almost half of the patients with
CA-MRSA infection are found to have at least one
risk-factor for healthcare-associated MRSA infec-
tion [15,19]. These risk-factors have been
identiﬁed as: recent hospitalisation, outpatient
status, nursing home admission, antibiotic
exposure, chronic illness, injection drug use and
close contact with a person with risk-factors [19].
For these reasons, it has been proposed to classify
community-onset MRSA as either truly commu-
nity-acquired or healthcare-associated [20].
CA-MRSA outbreaks have been documented in
several population groups and settings: correc-
tional facility inmates (associated with sharing of
personal items such as linens, and improper
diagnosis and medical care) [21,22]; sports partic-
ipants (associated with equipment- and sport-
related abrasions and lacerations, physical contact
and sharing of equipment) [23–25]; military per-
sonnel (associated with the signiﬁcant risk of soft-
tissue infection for an extended period of time)
[26,27]; and population groups with lower socio-
economic status (associated with crowded hous-
ing conditions and limited access to healthcare,
e.g., Native Americans) [28]. CA-MRSA infection
has also been associated with post-partum
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women, children in day-care programmes, injec-
tion drug users, men who have sex with men, and
homeless persons [16,29].
ANTIMICROBIAL TREATMENT
OPTIONS FOR STAPHYLOCOCCAL
INFECTIONS
b-Lactams are the preferred agents for the treat-
ment of infections caused by MSSA or suspected
MSSA, for reasons of overall patient safety,
convenience (oral availability) and cost [30].
Penicillinase-resistant, semi-synthetic penicillins,
such as ﬂucloxacillin, cloxacillin or dicloxacillin,
are the drugs of choice for deﬁnitive treatment of
MSSA in the UK and for use in empirical therapy
(except when MRSA is highly prevalent) [30]. In
the USA, the penicillinase-resistant penicillins
nafcillin and oxacillin are the parenteral drugs
of choice for infections caused by MSSA, whereas
dicloxacillin is the oral drug of choice [31]. First-
generation cephalosporins, such as cephalexin
and cefazolin, are also commonly used, especially
in penicillin-allergic patients [31].
Glycopeptides are currently the standard-of-
care antimicrobials for treatment of MRSA infec-
tions, particularly bacteraemia, complicated SSTIs
and bone infections [30]. These drugs have sig-
niﬁcant in-vitro activity against Gram-positive
pathogens, and vancomycin speciﬁcally is widely
used in the treatment of staphylococcal and
enterococcal infections [8]. However, in a large
prospective observational study, Chang et al.
showed that patients with MSSA bacteraemia
who received vancomycin therapy had a higher
rate of relapse and microbiological failure than
those who received nafcillin [32]. Therefore, the
use of glycopeptides in the treatment of infections
caused by MSSA is only recommended as an
option for penicillin-allergic patients [31].
The extensive use of glycopeptides in the past
has led to the discovery of glycopeptide-resistant
organisms and, consequently, recommendations
to restrict the use of these agents in the absence of
strong indications [33,34]. Vancomycin-resistant
enterococci (VRE) have emerged as important
clinical pathogens, particularly in the USA [8],
and many VRE isolates show resistance to teico-
planin, aminoglycosides (high-level) and b-lac-
tams, thus limiting the therapeutic options for
VRE infections [8]. In a global study, 75.2% of
Enterococcus faecium isolates in 2003 were resistant
to vancomycin (65.8% to teicoplanin), an increase
of almost 40% as compared with resistance rates
in 1997 [10].
Concerns have also emerged about the efﬁcacy
of vancomycin in the treatment of MRSA infec-
tions, due to increasing MICs for staphylococci,
poor tissue penetration and a slower rate of
bacterial killing than was recognised previously
[8]. Usually, decreased susceptibility of S. aureus
to vancomycin is accompanied by decreased
susceptibility to teicoplanin, further compromis-
ing treatment options [35]. VISA isolates have
been widely recognised in the past 10 years,
although retrospective testing indicates a longer-
term presence [10]. In contrast, the ﬁrst naturally
occurring, deﬁnitively VRSA isolate was reported
in the USA in June 2002 [36].
Vancomycin resistance is thought to be medi-
ated by cell-wall thickening or acquisition of the
vanA gene [34]. In VISA strains, the production of
excessive peptidoglycan with increased numbers
of D-alanyl–D-alanine residues can potentially
both sequester vancomycin molecules from
their bacterial target and impede the progress of
further vancomycin molecules through the cell
wall [34]. Resistance in VRSA strains has been
attributed to the acquisition of the vanA gene from
a conjugative plasmid in Enteroccus faecalis [36–
39]. This gene encodes VanA ligase, which is
required for the replacement of D-alanyl–D-ala-
nine residues in the peptidoglycan assembly
pathway with D-alanyl–D-lactate, a substitution
that prevents the binding of vancomycin to cell-
wall components [40]. Plasmid transfer of the
vanA gene from VRE to MRSA has been demon-
strated experimentally [41], but there is no evi-
dence yet for the subsequent transmission of
emergent VRSA strains [42].
Although VISA and VRSA (high-level resis-
tance to vancomycin) strains are rare among
clinical S. aureus isolates [43], there is evidence
that heterogeneous VISA (hVISA) strains may
be more common [44,45]. hVISA strains, the
acknowledged precursors of VISA strains, contain
sub-populations of S. aureus with MICs in the
intermediate range, resulting in a ‘combined’ MIC
falling between that of wild-type MRSA
(£ 2 mg ⁄L or susceptible) and VISA (8–16 mg ⁄L)
[10]. Data generated using techniques that pro-
vide population analysis proﬁles for suspected
hVISA suggest that up to 18% of S. aureus strains
with vancomycin MICs of 0.5–4.0 mg ⁄L are in fact
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heteroresistant [46]. Although the full clinical
relevance of hVISA is still under investigation
[47], a growing body of microbiological and
clinical data indicates that patients with S. aureus
isolates are less likely to respond to vancomycin
therapy when the vancomycin MICs are ‡ 4 mg ⁄L
[48].
In 2006, the CLSI reduced the vancomycin MIC
breakpoints in order to increase the detection of
heterogeneously resistant isolates [48]. The sus-
ceptibility breakpoint was lowered from £ 4 mg ⁄L
to 2 mg ⁄L, the intermediate breakpoint from
8–16 mg ⁄L to 4–8 mg ⁄L and the resistance break-
point from ‡ 32 mg ⁄L to ‡ 16 mg ⁄L [48]. Lower-
ing of the vancomycin MIC breakpoints for
S. aureus may improve the correlation between
the in-vitro deﬁnition of susceptibility and the
likelihood of a clinical response to vancomycin,
and facilitate the identiﬁcation of hVISA isolates
that may lead to treatment failure [48]. However,
it does not directly address the issues of vanco-
mycin tolerance and vancomycin MIC creep, and
the technical shortcomings of standard broth
microdilution, agar dilution and disk-diffusion
assays in the detection of hVISA.
Vancomycin tolerance, deﬁned as a minimum
bactericidal concentration (MBC):MIC ratio ‡ 32
or an MBC:MIC ratio ‡ 16 associated with a
resistant-level vancomycin MBC of ‡ 32 mg ⁄L,
represents a lack of bactericidal activity [10,49–
51]. It has been found to occur in S. aureus,
particularly MRSA, and can adversely affect the
outcome of antimicrobial therapy for serious
infections [49–51]. A signiﬁcant subset of S. aureus
strains is associated with the risk of clinical failure
due to vancomycin tolerance, regardless of the
reported susceptibility levels (MICs) [10]. In a
recent study of 213 S. aureus strains, 15% of wild-
type MRSA strains, 74% of hVISA strains and
100% of VISA and VRSA strains were tolerant to
vancomycin [10]. In contrast, when tested against
daptomycin, these strains had MBC:MIC ratios of
1 and 2, respectively, indicating the strong bacteri-
cidal activity of daptomycin against all strains
[10].
Large-scale surveillance programmes have
failed to recognise the phenomenon of vanco-
mycin MIC creep [10], but increasing MICs have
been reported by institutional-level surveys. For
instance, a survey of S. aureus isolates from
California, USA reported a shift in vancomycin
MIC values from £ 0.5 mg ⁄L to 1 mg ⁄L in the
5 years from 2000 to 2004, together with a
signiﬁcantly higher percentage of isolates with
an MIC of 1 mg ⁄L in 2004 than in 2000 (70.4%
vs 19.9%, p < 0.01) [43]. Furthermore, a 1.5-fold
increase in vancomycin MIC has also been
documented in MRSA blood isolates at the
New Hanover Medical Regional Center (Dela-
ware, USA), with a concomitant rise in the
percentage of isolates with an MIC of 1 mg ⁄L in
2005 as compared with 2001 (69% vs 16%,
p < 0.0001) [52].
Even with the new CLSI breakpoints, vanco-
mycin susceptibility testing may fail to accurately
differentiate between cases that are potentially
responsive and those with a higher likelihood of
clinical failure [10]. Vancomycin MIC results of
1.5–2 mg ⁄L have been shown to be an indepen-
dent predictor of a poor response to vancomycin
therapy in MRSA infections, even when sufﬁcient
trough levels of vancomycin were achieved [53].
In MRSA bacteraemia speciﬁcally, the increasing
vancomycin MIC, even within the new suscepti-
bility range, demonstrates a signiﬁcant risk of
vancomycin treatment failure [54]. For example,
in a well-conducted study, MRSA isolates with
vancomycin MICs of £ 0.5 mg ⁄L were associated
with 55.6% treatment success with vancomycin,
whereas MICs of 1–2 mg ⁄L resulted in 9.5%
treatment success with vancomycin [54]. In addi-
tion, vancomycin treatment failures associated
with modest MICs have been observed in other
studies of the treatment of MRSA endocarditis
[55] and of serious MRSA infections associated
with deep-seated infection [56]. Despite revisions,
the CLSI recommendations for testing vanco-
mycin still lack an acceptable degree of predicted
accuracy. Tracing the evolution of susceptibility
of MRSA to vancomycin may require more
accurate susceptibility testing, including the
direct assessment of bactericidal activity, or
alterations to the standard MIC method that
incorporate more precise dilution schedules.
Furthermore, local changes in the clonality of
endemic MRSA should be assessed along with
their effects on vancomycin MIC results.
NEED FOR NEW ANTIBIOTICS
The emergence of serious staphylococcal infec-
tions with reduced susceptibility to vancomycin
highlights the need for more antimicrobial
options with increased potency or enhanced
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bactericidal activity against MRSA, hVISA, VISA
and VRSA [8,33,57]. Only two new classes have
been introduced over the past few decades: the
oxazolidinones and the cyclic lipopeptides [58].
Among the antimicrobial agents that have more
recently been approved for clinical use, dapto-
mycin (a cyclic lipopeptide), linezolid (an oxazo-
lidinone) and tigecycline (a glycylcycline) have
activity against Gram-positive organisms, includ-
ing MRSA. With further clinical experience, these
new agents will be judged against several
properties that are considered to be ideal for
effective antimicrobials, as well as properties that
are desirable in any pharmaceutical agent: low
toxicity, a wide therapeutic index, multiple routes
of administration, favourable pharmacokinetics,
ﬂexible dosing, good combinability, and minimal
drug–drug interactions. In the context of compli-
cated staphylococcal infections, considerations
such as bactericidal activity and the potential for
development of resistance are of particular impor-
tance.
Bactericidal activity was considered to be one
of the most signiﬁcant beneﬁts of the penicillin
class. However, the subsequent rapid develop-
ment of penicillin resistance led to an increased
use of bacteriostatic agents or drugs with low
bactericidal activity, such as vancomycin and
linezolid [59]. There remain clinical indications
for which bactericidal compounds are considered
to be superior, i.e., endocarditis, meningitis and
infections in neutropenic patients [59]. In these
contexts, the speed of response is considered to be
critical and bactericidal antimicrobials should be
the ﬁrst treatment option [59]. Conceptually, the
use of bactericidal drugs in other, less serious
infections should also result in superior clinical
outcomes [59]. Activity in the stationary phase of
bacterial population growth is also beneﬁcial in
infections such as endocarditis, because the bac-
teria in cardiac vegetations, which are present at
very high densities, become dormant and less
susceptible to antimicrobial killing [60].
A low potential for the development of resis-
tance is a key requirement for new antimicrobial
agents and is one of the attractions of new classes
with novel mechanisms of action, because this
lowers the potential for cross-resistance [61]. The
unique mechanism of action of the cyclic lipopep-
tide class also demonstrates that bactericidal drugs
do not have to be bacteriolytic. Previously, the lysis
produced by bactericidal agents was considered to
be a disadvantage, due to the inﬂammatory reac-
tion that could result from release of intracellular
bacterial products, such as lipopolysaccharides
(Gram-negative organisms) and peptidoglycans
(Gram-positive organisms) [62].
CONCLUSION
The increasing prevalence of Gram-positive infec-
tions and antimicrobial-resistant strains in health-
care and community settings, especially MRSA,
are serious challenges faced in contemporary
medical practice. Use of the current standard
treatment for MRSA, vancomycin, has become
compromised, not just by the emergence of
VISA and VRSA strains, but also by vancomycin
tolerance and MIC creep associated with docu-
mented treatment failures. Consequently, there
is an emergent clinical need for new agents for
the treatment of infections caused by resistant
strains, and, ideally, new candidate antimicro-
bials should have potent bactericidal activity
and susceptibility proﬁles superior to those of
the currently used glycopeptides (vancomycin
and teicoplanin).
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